.jpg)
.png)
All
CHICAGO — In this video, James A. Underberg, MD, discusses recommendations from the National Lipid Association for patient-centric management of cholesterol abnormalities, and how they connect with the results of the IMPROVE-IT trial presented at the American Heart Association Scientific... more
Arrowhead Pharmaceuticals is proud to announce the publication of two back-to-back NEJM manuscripts in the mixed hyperlipidemia population with plozasiran (MUIR study with APOC3 target) and zodasiran (ARCHES2 study with ANGPTL3 target) following the EAS presentations by Drs. Ballantyne and... more
View the NLA & Chapter Board Resrouces below: 2020-2021 Board Resource Packet Orientation Webinar Orientation Webinar Slides × Close
The Journal of Clinical Lipidology announced on Monday its 2016 Impact Factor has risen to 5.812, up from 4.906 in 2015.
Anne Goldberg, MD, FACP, associate professor of medicine at Washington University School of Medicine, joins moderator Harold E. Bays, MD, FTOS, FACE, FNLA, to discuss the NLA Recommendations and ACC/AHA Guidelines regarding lipid evaluation and management. To view the content, log in to your... more
The National Lipid Association (NLA) and the American Society for Preventive Cardiology (ASPC) have released a joint clinical perspective in the Journal of Clinical Lipidology (JCL) and the American Journal of Preventive Cardiology (AJPC) strongly encouraging clinicians to recognize the... more
Discuss this article at www.lipid.org/lipidspin Clinical practice guidelines are integral to daily management of cardiovascular diseases, including hyperlipidemia. The most recent 2018 Multisociety Cholesterol Guidelines advocate for a more personalized approach to risk assessment.... more
The NLA is currently accepting nominations for Officer and At-Large positions for the NLA Board of Directors and all Chapter Boards of Directors. To submit an NLA or Chapter Board nomination, click here. All nominations are due on March 03, 2017.
For heart health, you're supposed to know your numbers: total cholesterol, the bad LDL kind and the good HDL kind. Associated Press - November 7, 2011
From ABC News: Drugmaker Merck & Co. said Tuesday that it's recalling a combination cholesterol drug, wiping out the entire U.S. stock, due to packaging defects that could reduce effectiveness. Merck said the recall covers all four dose strengths and every batch distributed since Liptruzet... more